Evaluating the economic benefits of robotic surgeryin the treatment of prostate cancer

Abstract

The care of diseases such as prostate cancer indicates the need for more and more revolutionary ways of treating the disease, in this sense, it was decided to carry out a systematic review study whose objective was to identify how the economic benefits of Robotic Surgery in the Treatment of Prostate Cancer are evaluated. To achieve this,
a search for publications was carried out with previously demarcated inclusion criteria, including the temporality from 2021 to 2023. This search was carried out in renowned databases including PubMed, Medline, Science direct, Scielo, Google Scholar and Academia, and in accordance with the provisions of the Preferred Reporting items for Systematic reviews and meta-Analyses (PRISMA) criteria, for which terms such as robotic surgery, prostate cancer
robotic assisted surgery costs were used and the Boolean operators "AND", "OR" and "NOT" were part of the formula, without language restrictions. From this, 151 documents were found, of which after performing four filtering phases, 10 articles were found. As part of the results, the average cost of robotic surgery was found, comparing at least six countries, and the benefits for patients and medical entities that offer the service were determined.
Concluding that, although this type of procedure is highly safe and precise, it is expensive, however, the advantages
it generates for both parties are exceptional, if we consider that variables such as precision, accuracy of processes
within the operating room, postoperative costs, as well as the reduction of effects associated with incontinence and
erection, are opportunities that occur with the performance of this type of surgery.